Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha/Beta T Cell and CD19+ B Cell Depletion in AlloSCT for Hematologic Diseases
NCT04099966Phase 2Recruiting
- Start
- Apr 2021
- Primary completion
- Dec 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in acute leukemia, aplastic anemia, non-Hodgkin lymphoma (NHL) and 7 more. Primary endpoint: Incidence of adverse events related to administration of α/β CD3+/CD19+ cell depleted stem cells at 1 year. Started Apr 2021; status: recruiting.
02
Conditions
acute leukemiaaplastic anemianon-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)severe congenital neutropenia (SCN)
Beyond the preview
Go deeper on NCT04099966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04099966.